154 related articles for article (PubMed ID: 36332)
1. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
[TBL] [Abstract][Full Text] [Related]
2. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF
Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884
[TBL] [Abstract][Full Text] [Related]
5. Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa.
Kolassa N; Becker R; Wiener H
Prostaglandins; 1985 Jan; 29(1):133-42. PubMed ID: 2858116
[TBL] [Abstract][Full Text] [Related]
6. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
Azadkhan AK; Truelove SC; Aronson JK
Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
[TBL] [Abstract][Full Text] [Related]
7. Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.
Pieniaszek HJ; BatesTR
Res Commun Chem Pathol Pharmacol; 1975 Nov; 12(3):571-81. PubMed ID: 747
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.
Chungi VS; Dittert LW; Shargel L
Pharm Res; 1989 Dec; 6(12):1067-72. PubMed ID: 2576130
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
10. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
Pieniaszek HJ; Bates TR
J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792
[TBL] [Abstract][Full Text] [Related]
11. [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
Kitano A; Tabata A; Obayashi M; Nakagawa M; Yasuda K; Fukushima R; Okabe H; Tomobuchi M; Nakamura S; Kashima K
Nihon Shokakibyo Gakkai Zasshi; 1993 Feb; 90(2):124-33. PubMed ID: 8096555
[TBL] [Abstract][Full Text] [Related]
12. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
Järnerot G; Into-Malmberg MB; Esbjörner E
Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
[TBL] [Abstract][Full Text] [Related]
13. A polymeric drug for treatment of inflammatory bowel disease.
Brown JP; McGarraugh GV; Parkinson TM; Wingard RE; Onderdonk AB
J Med Chem; 1983 Sep; 26(9):1300-7. PubMed ID: 6136612
[TBL] [Abstract][Full Text] [Related]
14. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
Das KM; Eastwood MA; McManus JP; Sircus W
Gut; 1973 Aug; 14(8):631-41. PubMed ID: 4147555
[TBL] [Abstract][Full Text] [Related]
15. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.
Gu GZ; Xia HM; Pang ZQ; Liu ZY; Jiang XG; Chen J
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):449-56. PubMed ID: 21251889
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
[TBL] [Abstract][Full Text] [Related]
17. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
Neumann VC; Taggart AJ; Le Gallez P; Astbury C; Hill J; Bird HA
J Rheumatol; 1986 Apr; 13(2):285-7. PubMed ID: 2873245
[TBL] [Abstract][Full Text] [Related]
18. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
[TBL] [Abstract][Full Text] [Related]
19. The role of the colon in the metabolism of salicylazosulphapyridine.
Das KM; Eastwood MA; McManus JP; Sircus W
Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
[No Abstract] [Full Text] [Related]
20. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y
Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
